Skip to content

CAlcified Lesion Intervention Planning Steered by OCT.

CAlcified Lesion Intervention Planning Steered by OCT.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05301218
Acronym
CALIPSO
Enrollment
140
Registered
2022-03-29
Start date
2021-12-15
Completion date
2023-12-15
Last updated
2022-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angioplasty, Coronary Artery Calcification

Keywords

Optical Coherence Tomography, OCT, minimal stent area(MSA)

Brief summary

Calcified lesions are very frequent among coronary artery disease stenotic lesions. The prevalence of calcifications ranges from 30 to 40% (by angiography evaluation) but is higher when analyzed by intra coronary imaging. Calcified lesions are very frequent among coronary artery disease stenotic lesions. The prevalence of calcifications ranges from 30 to 40% (by angiography evaluation) but is higher when analyzed by intra coronary imaging. The presence of calcifications increases the risk of adverse evolution after PCI , including stent restenosis, thrombosis and need for repeat revascularisation. Specific and appropriate tools can be used for calcified lesions management , including high pressure non compliant balloons, intravascular lithotripsy and rotablator. Intra vascular OCT has a high sensitivity and specificity for calcium detection among coronary artery lesions. Compared to IVUS, OCT allows a better quantification of calcium sheets (depth extension ) . Several intra coronary imaging based calcified lesions management algorithms have been proposed , but none have been validated in clinical practice.

Interventions

PROCEDUREangioplasty

Coronary angioplasty, also called percutaneous coronary intervention, is a procedure used to open clogged heart arteries. Angioplasty uses a tiny balloon catheter that is inserted in a blocked blood vessel to help widen it and improve blood flow to the heart

Sponsors

Abbott
CollaboratorINDUSTRY
Institut Mutualiste Montsouris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. Patient with chronic coronary syndrome 2. Angiographically moderately to severely calcified target lesion, defined as follows: * Moderate: lesion with radio-opacities noted only during the cardiac cycle before contrast dye injection (Aksoy et al., Circ Cardiovasc Interv 2019) * Severe: lesion with radio-opacities seen without cardiac motion before contrast dye injection, visible on both sides of the arterial lumen(Aksoy et al., Circ Cardiovasc Interv 2019) 3. Possibility to cross the target lesion with OCT catheter

Exclusion criteria

1. On-going cardiogenic shock 2. Acute coronary syndrome related to target lesion 3. Severe renal failure (Creatinine clearance: 30 ml/min/m2) 4. Impossibility to cross target lesion with OCT catheter & balloons, 5. Indication for Rotablator device as first line therapy 6. Pregnancy 7. Age \< 18 y 8. Denial to provide consent

Design outcomes

Primary

MeasureTime frameDescription
The primary endpoint of the CALIPSO study is the minimal stent area (MSA) on the final OCT runDuring the procedureThe crude minimal stent area (MSA) will be measured along the stent on the target lesion. Stent geometric expansion will be evaluated by the DOCTORS criteria for non-bifurcated segments (Meneveau et, Circulation 2016) and LEMON criteria for bifurcated segments (Amabile et al;, Eurointervention 2020).

Secondary

MeasureTime frameDescription
Residual post PCI (Percutaneous Coronary Intervention)stenosis (assessed by QCA methods)during procedureQualitative Comparative Analysis (QCA) is a methodology that enables the analysis of multiple cases in complex situations
Residual major struts malapposition: crude incidence and quantificationduring proceduremalapposition was defined as a lack of contact of at least 1 strut with the underlying vessel wall (at least 150 μm, in the absence of a side branch) with evidence of blood flow behind the strut. It was classified as major malapposition if there was evidence of at least 30% of the struts in one frame.
Major adverse cardiovascular events at 30 days and 1 yearat 30 days and 1 yearCardiovascular death + Any myocardial infarction + need for re-intervention on the target lesion (TLR)
Peri-procedural MI according to the SCAI definition (23)during procedureaccording to the SCAI definition (Moussa et al., Journal of the American College of Cardiology 2013)
Geometrical stent expansion (%) according to the DOCTORS or LEMON criteriaduring procedureAfter the stent is deployed, the blood flow dynamics influence the mechanics by compressing and expanding the structure.
Radiation doseduring procedureDifferences in dose radiation used during le procedure
Total Contrast medium volumeduring procedureDifferences in amount of contrast drug used during le procedure
Procedure duration24th post-operative hourdifferences in duration (time) of the procedure
Coronary artery perforation: incidenceduring the procedure and During the full participation period (1 year).]Coronary perforation was defined as evidence of extravasation of dye or blood from the coronary artery during or following the interventional procedure

Countries

France

Contacts

Primary ContactNicolas Amabile, MD PhD
nicolas.amabile@imm.fr0156616983
Backup ContactSilvia Burbassi, PhD
silvia.burbassi@imm.fr0156616983

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026